| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
1 company
Marshman Fund Trust II last filed a Form 4 in November 2024, as 10% Owner at HRMY.
At the last filing, the largest reported position was 6,051,120 shares of HRMY. The HRMY filings lean toward selling, a net 4,260,524 shares.
Marshman Fund Trust II has 3 Form 4 filings on record from August 2020 to November 2024, all as 10% Owner at Harmony Biosciences (HRMY), 2020–2024.
The 4 reported transactions were 2 open-market sales, 1 conversion and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $8.1M and 1 sale worth about $139.4M.
The only open-market purchase was 339,476 shares of HRMY at an average $24.00 on August 21, 2020, about $8.1M.
The only open-market sale was 4,600,000 shares of HRMY at an average $30.30 on November 5, 2024, about $139.4M. Twelve months later HRMY was down 6%.
Shares as reported in the last Form 4 for each company; the most recent is from November 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.